The global vagal nerve stimulation (VNS) market is projected to reach US $ 1.194 billion by 2026, showing a CAGR of 11.4% during the forecast period. The global epidemic of epilepsy and non-communicable brain disease is projected to drive the growth of this market. A recent Fortune Business Insights ™ report states: Vagal Maneuver (VNS) Market Size, Share and Industry Analysis, Type (Invasive and Non-Invasive {nVNS}), Application (Epilepsy, Treatment-Resistant Depression (TRD)) By end user (hospitals and specialty clinics), and regional forecasts, 2019-2026 ". The World Health Organization (WHO) estimates that nearly 50 million people worldwide suffer from epilepsy, of which nearly 80% live in low- and middle-income countries. WHO believes that 70% of people with epilepsy can lead a seizure-free life with proper treatment. Vagal nerve stimulation technology is steadily emerging as an effective treatment option for epilepsy. In the VNS method, a pulse stimulator is placed on the left vagus nerve. This sends a mild electrical stimulus to suppress the irregular and seizure-inducing brain activity of epileptic patients. Therefore, the proven effectiveness of VNS technology in the treatment of epilepsy has increased demand in healthcare and is driving trends in the vagal nerve stimulation market.
Request a sample copy of the research report:
https://bit.ly/3oTqLYq
Notable companies featured in the report:
tVNS Technologies GmbH
Parasym Ltd
Biological Control
Innovative Health Solutions INC
Electrocore Co., Ltd.
LivaNova PLC
Market constraints Costly
treatment procedures to weaken market outlook
"The high cost of VNS treatment can hinder the growth of the VNS market," said one of our lead analysts. I am. The Chicago-based Epilepsy Foundation states that VNS therapy costs about $ 20,000, including surgery and implants. The procedure is covered by insurance, but most people are not yet insured and may therefore not be able to afford treatment. In addition, a study published in the New England Journal of Medicine found that nearly 33% of epilepsy patients suffer from drug-resistant epilepsy. These patients need more and better medical care over a long period of time and may prove to be costly for the average patient who may not be able to afford to complete treatment. I have. Another major constraint is the lack of awareness and access to advanced treatments for neurological disorders in developing countries, which could significantly limit the expansion of this market during the forecast period.
Quick Buy
https://www.fortunebusinessinsights.com/checkout-page/101184
Regional Analysis
Patient-Friendly Reimbursement Policy to
Drive the North American Market 2018 Market Size US $ 244.7 Million, North America 10 Years Next We are poised to dominate the market share of vagal maneuver. The main reason for its command position is a favorable health compensation policy for VNS devices in the region. In addition, the high awareness of neurological disorders and the availability of advanced VNS technology will further drive the North American market.
Europe is projected to grow at an impressive CAGR due to the increasing issuance of CE certifications for non-invasive VNS procedures. According to the Vagal Maneuver Market Report, the Asia Pacific region is an undeveloped region in the context of this market, which opens up several opportunities for domestic and global players.
Industry Development:
June 2019: US-based Innovative Health Solutions has received FDA approval for IB-Stim devices. This device is designed to manage irritable bowel syndrome (IBS) in children and adolescents between the ages of 11 and 18. Non-surgical products are placed behind the patient's ear, allowing electrical pulses to be emitted to the cranial nerve clusters. ear.
November 2018: The US FDA is electroCore, Inc., a US-based medical company specializing in bioelectronics. GammaCore, a non-invasive vagal nerve stimulator (nVNS) developed by, was given 501 (k) clearance. This treatment is indicated for supplemental use to prevent the development of cluster headaches in adults.
Do you have any questions? Ask an expert:
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/vagus-nerve-stimulation-vns-market-101184